Kalif Eliyahu Sharon 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

Teva (TEVA) CFO Kalif Eliyahu Sharon Converts RSUs, Receives New RSU Grant

What Happened

Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd., had restricted share units (RSUs) vest and convert into ordinary shares on March 4, 2026, and received a new RSU grant the same day. Specifically, 33,512 RSUs (from a 2022 grant) and 23,251 RSUs (from a 2024 grant) were reported as converted/treated as exercised on 2026-03-04 (total converted = 56,763). A new grant of 53,175 RSUs was awarded on 2026-03-04.
The reported exercise/conversion entries show $0 or N/A for prices and the disposition entries are recorded at $0 — this reflects conversion/settlement of derivatives (no cash sale proceeds are shown). The Form 4 does not report a cash purchase or an open-market sale tied to these conversions.

Key Details

Transaction date: March 4, 2026 (all entries); Form 4 filed March 6, 2026 (timely filing).
Converted/vested RSUs: 33,512 and 23,251 (total 56,763). New RSU grant: 53,175.
Prices/values: Reported as $0 or N/A on the Form 4; no dollar proceeds were reported for the conversions.
Shares owned after transaction: Not provided in the data you supplied.
Notable footnotes:
- F1: Ordinary shares may be represented by American Depositary Shares (each currently equals one ordinary share).
- F2: Each RSU represents a contingent right to receive one ordinary share or, at the committee’s option, cash on settlement.
- F3–F5: Describe the original grant dates and vesting schedules for the 2022, 2024 and 2026 grants referenced above.
Filing timeliness: Filed two days after the transactions (typical reporting window); no late filing flag indicated.

Context

RSU vesting/conversion and new RSU grants are compensation-related events, not open-market purchases or sales. Conversions recorded as derivative dispositions at $0 commonly reflect settlement of RSUs into shares (and sometimes tax withholding) rather than a cash sale; the filing shows no separate market sale of the converted shares.
For retail investors, awards and vesting indicate executive compensation activity but are not direct bullish/bearish trading signals.

Form 4

Period: 2026-03-04

EVP, Chief Financial Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+33,512→ 282,268 total
Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+23,251→ 305,519 total
Exercise/Conversion
Restricted Share Units
[F2][F3][F1]
2026-03-04−33,512→ 0 total
→ Ordinary Shares (33,512 underlying)
Exercise/Conversion
Restricted Share Units
[F2][F4][F1]
2026-03-04−23,251→ 46,503 total
→ Ordinary Shares (23,251 underlying)
Award
Restricted Share Units
[F2][F5][F1]
2026-03-04+53,175→ 53,175 total
→ Ordinary Shares (53,175 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
[F4]Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028.
[F5]Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif|2026-03-06

1 file